Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (330)	2/3/2002 3:06:22 PM
From: nigel bates	Respond to of 1022

how would one know that phage display technology had played a part in the development of a monoclonal antibody? Take a look at the companies that have licences from DYAX. <g> D2E7 is expected 2nd qtr. this year, I think. nig

To: aknahow who wrote (330)	2/3/2002 3:25:13 PM
From: keokalani'nui	Respond to of 1022

One would not know in general, only if drug's sponsor disclosed it. Yet I think every company with a Mab of any type, chimeric, humanized, or fully human (mouse or phage) in clinical development would disclose, or has disclosed, its origination, since this would be of interest to many for many reasons. There have been plenty of review articles describing all Mabs in development, get your hands on one of those and track 'em down. You can pretty much figure that anyone claiming a fully human Mab who does not have a license from abgx, medx, deltagen or genmab (or Charles R.?) is using phage.